Monthly SOM230C for Recurrent or Progressive Meningioma

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 18% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularmriheartfailurect
  Phrases that lowered it: participantsadministrationthe purposepurpose ofperiod
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 9 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (lowers risk) · Drug's FDA history
• Disease area, dermatology: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma NCT00813592 · started 2008 · scored riskier than 98% of active trials terminated
• Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas NCT02333565 · started 2015 · scored riskier than 98% of active trials completed
• Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size NCT02021942 · started 2012 · scored riskier than 98% of active trials completed
• AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas NCT02831257 · started 2016 · scored riskier than 97% of active trials completed
• A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma NCT03016091 · started 2018 · scored riskier than 89% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.